AXA Beheer
Beheer criteriumcontroles 4/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Thomas Buberl
Algemeen directeur
€6.1m
Totale compensatie
| Percentage CEO-salaris | 26.85% |
| Dienstverband CEO | 10yrs |
| Eigendom CEO | 0.07% |
| Management gemiddelde ambtstermijn | 4.6yrs |
| Gemiddelde ambtstermijn bestuur | 6.3yrs |
Recente managementupdates
Recent updates
Narratiefupdate • Sep 03
CS: Higher Earnings Multiple Will Be Supported By AI Governance Progress
Analysts have lifted the fair value estimate for AXA to €66.18 from €64.68, reflecting higher Street price targets that now reach up to €77.10 as they point to updated assumptions on revenue growth, profit margins and future P/E multiples. Analyst Commentary Recent Street research on AXA points to a cluster of higher price targets and supportive ratings that highlight constructive views on the stock.Narratiefupdate • Aug 13
CS: Raised Price Views Will Support A Higher Future Earnings Multiple
AXA’s updated analyst price target has risen to €64.68 from €62.41. This reflects adjustments in fair value, discount rate, revenue growth, profit margin and future P/E that are broadly consistent with recent target increases from several research firms.
Narratiefupdate • Jul 30
CS: Higher Revenue Assumptions And Lower Discount Rate Will Test Execution
AXA's analyst price target has increased to €42.40 from €40.00, with analysts citing updated assumptions for revenue growth, margins, P/E and discount rates that are broadly consistent with recent upward revisions to Street targets in the range of approximately €50 to €77.10 per share. Analyst Commentary Recent Street research on AXA shows a wide spread in price targets, ranging from around €50 to €77.10 per share.
Narratiefupdate • Jul 16
CS: Updated Fair Value And P/E Assumptions Will Shape Balanced Re Rating
AXA's analyst price target has been nudged higher to €50, with analysts pointing to slightly adjusted fair value estimates, updated revenue growth and margin assumptions, and modestly refined future P/E expectations as key factors supporting the change. Analyst Commentary Recent research commentary on AXA points to a mixed but generally constructive view, with several price target increases and one reduction reflecting different opinions on valuation, growth assumptions, and execution risk.Nieuw narratief • Jun 30
Climate And Aging Trends Will Shape Insurance Demand While Returns Stay Steady
Catalysts About AXA AXA is a global insurance group offering property and casualty, life, health, savings and retirement products to retail clients, businesses and institutions. What are the underlying business or industry changes driving this perspective?Narratiefupdate • Jun 18
CS: Higher Fair Value And P/E Assumptions Will Support Measured Re Rating
Analysts have nudged the fair value estimate for AXA higher to €47.51 from €46.48, citing a series of upward revisions to price targets, including recent increases to around €77.10 from €57.40 and by €1 in other Street updates, alongside broadly supportive new coverage. Analyst Commentary Recent Street research on AXA offers a mix of optimism and caution that investors can weigh against the revised fair value estimate.Nieuw narratief • Jun 15
AI And Climate Risk Tailwinds Will Reshape This Global Insurer’s Next Decade
Catalysts About AXA AXA is a global insurance group active in Property & Casualty, Life, Health, Savings and reinsurance across Europe, Asia, Africa and other markets. What are the underlying business or industry changes driving this perspective?Narratiefupdate • Jun 03
CS: Higher Fair Value And P/E Assumptions Will Support Measured Re Rating
AXA's analyst price target has edged higher by about €0.35, with analysts pointing to modestly revised assumptions around fair value, discount rate, profit margin and future P/E. This move is supported by recent research that includes both a €1 target increase and a €1 reduction from different banks, alongside a bullish initiation.Narratiefupdate • May 08
CS: Technical And Fee-Based Shift Plus Buybacks Will Support Measured Re-Rating
AXA's fair value estimate edges higher to €46.12 from €46.07 as analysts refine assumptions around revenue growth, profit margins and future P/E, supported by a series of recent price target increases and bullish initiations on the stock. Analyst Commentary Recent Street research around AXA has been active, with several price target revisions and fresh initiations feeding into the updated fair value estimate.Narratiefupdate • Apr 22
CS: Technical And Fee-Based Earnings Mix Will Support Re-Rating As Discount Persists
Analysts have nudged their average price target for AXA slightly higher to about €46.07. This reflects modest tweaks to assumptions around discount rates, profit margins and future P/E multiples, alongside recent Street research that includes both upward and downward target revisions clustered around the €46 to €50 range.Narratiefupdate • Apr 07
CS: Technical And Fee-Based Earnings Shift Will Support Re-Rating As Discount Persists
AXA's analyst price targets have edged higher into a €46 to €50.70 range, as analysts point to improved profitability from technical insurance and fee-based earnings, along with what they view as an ongoing discount to European composite peers. Analyst Commentary Recent research points to a cluster of higher price targets for AXA, with analysts largely focused on the mix of technical insurance and fee-based earnings and how that feeds into profitability, earnings stability, and valuation relative to European peers.Narratiefupdate • Mar 24
CS: Technical And Fee-Based Shift Will Support Re-Rating As Discount Persists
Analysts have nudged AXA's average price target higher to around €48 to €51, citing improved profitability from its focus on technical insurance and fee-based earnings and pointing out that the current valuation still sits at a discount to European composite peers. Analyst Commentary Recent Street research has tilted positive on AXA, with several banks lifting their price targets into a relatively tight band between €46 and about €51.Narratiefupdate • Mar 10
CS: Technical And Fee-Based Shift Will Support Re-Rating Versus European Composite Peers
Our AXA fair value estimate has been adjusted from €45.27 to €46.05. This reflects higher analyst price targets in the €46 to €50.70 range and their focus on improved profitability, lower earnings volatility and a reduced P/E assumption.Narratiefupdate • Feb 23
CS: Technical And Fee-Based Shift Will Support Higher Future Earnings Multiple
Analysts have nudged their price target for AXA slightly higher to about €45.27 from roughly €45.11, citing continued focus on technical insurance and fee-based earnings that they say is supporting improved profitability and a higher assumed future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts point to the shift towards technical insurance and fee-based earnings as a key support for more stable and higher quality profit streams, which they see as supportive of a stronger P/E multiple over time.Narratiefupdate • Feb 08
CS: Slightly Lower Discount Rate Will Support Forward Earnings Appeal
The analyst fair value estimate for AXA has been adjusted slightly higher to €45.11 from €45.06, as analysts refine their assumptions around discount rates, revenue growth, profit margins and future P/E multiples. Valuation Changes Fair Value Estimate adjusted slightly higher to €45.11 from €45.06.Narratiefupdate • Jan 24
CS: Stable Assumptions And Slightly Higher Required Return Will Support Forward Earnings Appeal
Analysts have slightly raised their fair value estimate for AXA to €45.06 from €44.98, citing adjusted assumptions for the discount rate, revenue growth, profit margin and future P/E that together support a marginally higher price target. Valuation Changes Fair value estimate is now set at €45.06, up slightly from €44.98, reflecting a very small adjustment in the model.Narratiefupdate • Jan 10
CS: Stable Assumptions And Slightly Lower P/E Will Support Forward Earnings Appeal
Analysts have reduced their price target for AXA slightly to about €45, reflecting small adjustments to fair value estimates, discount rate assumptions and future P/E expectations, while keeping revenue growth and profit margin forecasts broadly unchanged. Valuation Changes Fair Value: Adjusted slightly from €45.07 to €44.98, indicating a very small reduction in the estimated fair value per share.Narratiefupdate • Dec 17
CS: Lower Discount Rate Will Support Stronger Forward Earnings Appeal
Analysts have nudged their price target on AXA slightly higher to approximately €45.07 from about €45.04, citing a marginally lower discount rate and modest improvements in projected profit margins that together support a slightly richer valuation multiple. Valuation Changes Fair Value has risen slightly from approximately €45.04 to about €45.07, reflecting a marginal uplift in the intrinsic valuation estimate.Narratiefupdate • Dec 03
CS: Modestly Higher Future Multiple Will Support Attractive Upside Potential
Analysts have modestly raised their price target on AXA to €45.04, citing a slightly higher assumed future price to earnings multiple, which more than offsets marginal adjustments to the discount rate and profit margin forecasts. Valuation Changes Fair Value Estimate unchanged at approximately €45.04 per share, indicating no revision to the intrinsic value assessment.Narratiefupdate • Nov 19
CS: Strong Profit Margins And Stable P/E Will Drive Future Gains
Analysts have slightly raised their price target for AXA, increasing it from €44.96 to €45.04. This change is based on modest adjustments to projected revenue growth, profit margins, and discount rates.Narratiefupdate • Nov 02
CS: Rising Profit Margins And Multiples Will Drive Global Expansion
Analysts have slightly raised their price target for AXA from €44.58 to €44.96, citing incremental improvements in profit margin and expected future earnings multiples as key factors supporting the revision. Valuation Changes Fair Value has increased slightly from €44.58 to €44.96.
Nieuw narratief • Nov 07
Calculated Market Expansion And Innovative Products Drive Revenue Growth And Profitability
AXA's disciplined pricing and focus on operational excellence aim to enhance profitability in international markets.Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | €8b |
| Mar 31 2026 | n/a | n/a | €7b |
| Dec 31 2025 | €6m | €2m | €7b |
| Sep 30 2025 | n/a | n/a | €7b |
| Jun 30 2025 | n/a | n/a | €7b |
| Mar 31 2025 | n/a | n/a | €7b |
| Dec 31 2024 | €6m | €2m | €7b |
| Sep 30 2024 | n/a | n/a | €7b |
| Jun 30 2024 | n/a | n/a | €7b |
| Mar 31 2024 | n/a | n/a | €7b |
| Dec 31 2023 | €6m | €2m | €7b |
| Sep 30 2023 | n/a | n/a | €6b |
| Jun 30 2023 | n/a | n/a | €5b |
| Mar 31 2023 | n/a | n/a | €5b |
| Dec 31 2022 | €5m | €2m | €5b |
| Sep 30 2022 | n/a | n/a | €6b |
| Jun 30 2022 | n/a | n/a | €7b |
| Mar 31 2022 | n/a | n/a | €7b |
| Dec 31 2021 | €5m | €1m | €7b |
| Sep 30 2021 | n/a | n/a | €6b |
| Jun 30 2021 | n/a | n/a | €6b |
| Mar 31 2021 | n/a | n/a | €4b |
| Dec 31 2020 | €4m | €1m | €3b |
| Jun 30 2020 | n/a | n/a | €3b |
| Mar 31 2020 | n/a | n/a | €3b |
| Dec 31 2019 | €5m | €3m | €4b |
Compensatie versus markt: De totale vergoeding ($USD 7.12M ) Thomas } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de French markt ($USD 5.64M ).
Compensatie versus inkomsten: De vergoeding van Thomas is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Thomas Buberl (53 yo)
10yrs
Tenure
€6,144,119
Compensatie
Dr. Thomas Buberl, Ph D., serves as Advisory Board Member at Planet First Partners Gérant Sàrl. He is Independent Director of International Business Machines Corporation from April 28, 2020.Dr. Buberl is...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 10yrs | €6.14m | 0.066% € 58.0m | |
| Group General Counsel & Employee Shareholders Representative Director | 10.3yrs | €106.42k | 0.011% € 9.5m | |
| Group Chief Financial Officer | 5.2yrs | geen gegevens | geen gegevens | |
| Chief Accounting & Reporting Officer | no data | geen gegevens | geen gegevens | |
| Group Chief Technology & AI Officer | 1.7yrs | geen gegevens | geen gegevens | |
| Group Chief Strategy Officer & Head of Investor Relations | 4yrs | geen gegevens | geen gegevens | |
| Group Chief Communication | 7.5yrs | geen gegevens | geen gegevens | |
| Group Chief Human Resources Officer | no data | geen gegevens | geen gegevens | |
| Chief Executive Officer of International Markets | no data | geen gegevens | geen gegevens | |
| Global Head of Finance | 1.7yrs | geen gegevens | geen gegevens | |
| Chief Executive Officer of European Markets & Health | 9.8yrs | geen gegevens | geen gegevens | |
| Chief Transformation Officer for European Markets & Health | 3.2yrs | geen gegevens | geen gegevens |
4.6yrs
Gemiddelde duur
53yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van CS wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.6 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 10yrs | €6.14m | 0.066% € 58.0m | |
| Group General Counsel & Employee Shareholders Representative Director | 6.3yrs | €106.42k | 0.011% € 9.5m | |
| Honorary Chairman | 16.4yrs | geen gegevens | geen gegevens | |
| Independent Director | 10.4yrs | €172.04k | 0.00036% € 314.6k | |
| Director | 4.4yrs | €171.05k | 0.024% € 21.0m | |
| Independent Director | 5.4yrs | €233.81k | 0.00037% € 323.3k | |
| Independent Director | 5.4yrs | €173.92k | 0.00025% € 218.5k | |
| Independent Chairman of the Board | 6.3yrs | geen gegevens | 0.00021% € 183.5k | |
| Employees Representative Director | 8.3yrs | €106.42k | 0.000020% € 17.5k | |
| Employees Representative Director | 8.3yrs | €140.17k | 0.00017% € 148.5k | |
| Independent Director | 1.7yrs | €184.14k | 0.00010% € 87.4k | |
| Independent Director | 6.3yrs | €140.17k | 0.00020% € 174.8k |
6.3yrs
Gemiddelde duur
61.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van CS wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.3 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/13 07:21 |
| Aandelenkoers aan het einde van de dag | 2026/09/11 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
AXA SA wordt gevolgd door 34 analisten. 13 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Markus Mayer | Baader Helvea Equity Research |
| null null | Banco de Sabadell. S.A. |
| Valvanera Gómez Pastor | Banco Santander |